Drug intelligence / Profile preview

azelaic acid + doxycycline

Development stage
Unknown
Lead developer
Bayer
Modality
Small Molecules
Administration
Topical, Oral
01

Overview

**Azelaic acid + doxycycline** is a non-branded combination therapy used primarily in dermatology for the treatment of mild-to-moderate and moderate-to-severe papulopustular rosacea. Azelaic acid is a topical dicarboxylic acid with anti-inflammatory, antimicrobial, and antioxidant properties. It inhibits tyrosinase, mitochondrial respiratory chain enzymes, DNA synthesis, and the cathelicidin pathway, reducing inflammation and skin lesions[4][3][8]. Doxycycline is a tetracycline-class oral antibiotic that also provides anti-inflammatory benefits at sub-antimicrobial dosing. Together, topical azelaic acid (typically 15% gel) and oral doxycycline (typically 40–100 mg/day) exhibit additive or synergistic effects, leading to improved lesion reduction and faster onset of action compared to monotherapy, without significant additional adverse effects. This combination is supported by clinical studies for rosacea and is sometimes used off-label for other inflammatory dermatological conditions[1][2][3][7][9].

Other names
azelaic acid + doxycycline
02

Targets

Bacterial RibosomeTXNRD2 (Thioredoxin reductase 2)TYR (Tyrosinase)CAMP (Cathelicidin antimicrobial peptide)

Beyond the preview

Go deeper on azelaic acid + doxycycline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on azelaic acid + doxycycline.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call